PPTA Twitter

PlasmaProteins #TBT to PPTA’s interview with Val Bias, the former CEO of @NHF_Hemophilia to get a glimpse into the future for those living with #bleedingdisorders . Read more: bit.ly/2DZQ7Np pic.twitter.com/Fq9dRMJLLH
2 days ago.
PlasmaProteins “Ultimately, what drives my colleagues on the Board, my company, and the staff at PPTA is a focus on patients...” Karen Etchberger, of @CSLBehring , reflects on her election as Chair of @plasmaproteins Global Board of Directors. bit.ly/2u61VeZ pic.twitter.com/QKhDPwL1e0
9 days ago.

Public Workshop Focuses on Immune Globulin Products

On Nov. 8-9, the U.S. Food and Drug Administration (FDA) is conducting a public workshop entitled "Immune Globulin Potency in the 21st Century." The purpose of the public workshop is to discuss new challenges to meet U.S. potency requirements for Immune Globulin (IG) products and to identify measures to address these challenges.

The workshop has been planned in partnership with the Immune Deficiency Foundation (IDF) and the Plasma Protein Therapeutics Association (PPTA). The workshop will include presentations and panel discussions by experts from academic institutions, industry, and government agencies.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100